Literature DB >> 12553056

Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat.

G Cavaletti1, M G Petruccioli, P Marmiroli, R Rigolio, S Galbiati, C Zoia, C Ferrarese, E Tagliabue, C Dolci, M Bayssas, G Griffon Etienne, G Tredici.   

Abstract

BACKGROUND: Oxaliplatin neurotoxicity represents a clinically-relevant problem and its etio-pathogenesis is still unknown. We explored the possible role of some neuronal growth factors ("neurotrophins") during the course of oxaliplatin sensory neuronopathy.
MATERIALS AND METHODS: In our rat model two different doses of oxaliplatin were used (2 and 3 mg/kg i.v. twice weekly for 9 times). The neurotoxicity of the treatment was assessed with neurophysiological and pathological methods and serum neurotrophin levels were measured by ELISA.
RESULTS: Both oxaliplatin-treated groups showed the neurophysiological and neuropathological changes which mimic the chronic effects of oxaliplatin administration in humans, e.g. reversible sensory impairment due to dorsal root ganglia neuron damage. These changes were associated with a significant and dose-dependent reduction only in the circulating level of nerve growth factor (NGF), which returned to normal values after neurophysiological and pathological recovery.
CONCLUSION: This specific association between neurological impairment and NGF modulation indicates that NGF impairment has a role in the neurotoxicity of oxaliplatin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12553056

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Drosophila melanogaster: a new model to study cisplatin-induced neurotoxicity.

Authors:  Jewel L Podratz; Nathan P Staff; Dara Froemel; Anna Wallner; Florian Wabnig; Allan J Bieber; Amy Tang; Anthony J Windebank
Journal:  Neurobiol Dis       Date:  2011-04-15       Impact factor: 5.996

2.  Low-level laser therapy alleviates mechanical and cold allodynia induced by oxaliplatin administration in rats.

Authors:  Y-L Hsieh; Y-C Fan; C-C Yang
Journal:  Support Care Cancer       Date:  2015-05-26       Impact factor: 3.603

3.  Clinical and experimental study of oxaliplatin in treating human gastric carcinoma.

Authors:  Wan-Long Lin; Ding-Guo Li; Qiang Chen; Han-Ming Lu
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

Review 4.  The challenges of colorectal cancer survivorship.

Authors:  Crystal S Denlinger; Andrea M Barsevick
Journal:  J Natl Compr Canc Netw       Date:  2009-09       Impact factor: 11.908

5.  Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice.

Authors:  Cynthia L Renn; Valentina A Carozzi; Peter Rhee; Danisha Gallop; Susan G Dorsey; Guido Cavaletti
Journal:  Mol Pain       Date:  2011-04-26       Impact factor: 3.395

6.  Histopathological and biochemical assessment of liver damage in albino Wistar rats treated with cytotoxic platinum compounds in combination with 5-fluorouracil.

Authors:  Nusrat Bano; Rahila Najam
Journal:  Arch Med Sci       Date:  2019-06-20       Impact factor: 3.318

7.  Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer.

Authors:  De-Shen Wang; Zhi-Qiang Wang; Gong Chen; Jie-Wen Peng; Wei Wang; Yan-Hong Deng; Feng-Hua Wang; Jian-Wei Zhang; Han-Lin Liang; Fen Feng; Chuan-Bo Xie; Chao Ren; Ying Jin; Si-Mei Shi; Wen-Hua Fan; Zhen-Hai Lu; Pei-Rong Ding; Feng Wang; Rui-Hua Xu; Yu-Hong Li
Journal:  Cancer Med       Date:  2019-11-13       Impact factor: 4.452

8.  Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli.

Authors:  Lauren E Ta; Philip A Low; Anthony J Windebank
Journal:  Mol Pain       Date:  2009-02-26       Impact factor: 3.395

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.